- Company Also Announces Participation in Upcoming Investor Conferences in
SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for November 2008, which includes the teleconference and webcast of its third quarter 2008 financial results as well as upcoming corporate presentations at noteworthy investor conferences.
On November 6, 2008 at 5:00 p.m. Eastern time, Orexigen management will
host the call and webcast to discuss the financial results for the third
quarter ended September 30, 2008, and recent business highlights. The live
call may be accessed by calling 800-860-2442 (domestic) or 412-858-4600
(international). The webcast can be accessed live on the investor relations
section of the Company's web site at http://www.orexigen.com and will be
archived for 14 days following the call.
Upcoming Corporate Presentations
Rodman & Renshaw 10th Annual Healthcare Conference
New York Palace Hotel, New York
November 11, 2008
2:00 p.m. EST
Lazard Capital Markets 5th Annual Healthcare Conference
St. Regis Hotel, New York
November 18, 2008
11:25 a.m. EST
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved